NILO-PD: A Phase 2A Study of Nilotinib in Patients with Moderately Advanced Parkinson’s Disease: Exploratory Efficacy Outcomes
Objective: To report secondary and exploratory analysis of efficacy of nilotinib in moderate/advanced Parkinson’s disease (PD) participants enrolled in NILO-PD study. Background: Previously completed studies…Auxilin knockout mice: a model for Parkinsonism with dopamine dysregulation and synucleinopathy
Objective: To evaluate the role of auxilin in the pathogenesis of Parkinson’s disease (PD). Background: Auxilin or DNAJC6, a brain-specific co-chaperone plays central role in…Characterization of striatal dopaminergic neurotransmission in the rat pre-formed fibril models of Parkinson’s disease
Objective: To determine the longitudinal effects of synucleinopathy and synucleinopathy-triggered nigrostriatal degeneration on basal and evoked striatal dopamine (DA) release in the striatum at 4…Gut Microbiote Distinctive Features and Microbiota-Metabolome Profile in Parkinson’s Disease: Focus on Levodopa and LCIG
Objective: The aim of this work was to study the microbiome of PD patients, studying the effect of dopaminergic drugs mainly focusing on the effect…Relationship Between a-syn RT-QuIC and a-syn Neuropathologic Burden in Dementia with Lewy Bodies
Objective: To determine if measures of alpha-synuclein (a-syn) real time quaking induced conversion (RT-QuIC) activity are related to a-syn neuropathologic burden in dementia with Lewy…Intrastriatal injection of alpha-synuclein preformed fibrils results in cognitive dysfunction and L-DOPA reversible sensorimotor impairments in rats
Objective: To determine the effect of intrastriatal injection of alpha-synuclein (aSyn) preformed fibrils (PFFs) on sensorimotor and non-motor function in rats. Background: The ideal animal…Selective α-synuclein overexpression-induced pathology in noradrenergic neurons: a new mouse model for prodromal Parkinson’s disease?
Objective: To investigate the phenotype of noradrenergic (NA) neurons in an animal model with selective overexpression of α-synuclein (αSyn) in the locus coeruleus (LC) with…Characterization of novel alpha-synuclein aggregation model of Parkinson’s disease
Objective: To establish and characterize a robust alpha-synuclein (aSyn) aggregation pathology research model to allow efficient drug development platform for Parkinson's disease (PD). Background: PD…Targeted deep sequencing of brain DNA for detection of somatic point mutations in synucleinopathies
Objective: To detect relevant somatic "point mutations" (single nucleotide variants- SNVs) in brain-derived DNA in synucleinopathies. Background: There is increasing recognition that neurons may harbour…Systematic Assessment of 10 diagnostic marker candidates in biological fluids for Parkinson’s disease
Objective: To validate in serum and/or cerebrospinal fluid (CSF) diagnostic biomarker candidates identified from a systematic literature search including markers on axonal and synaptic integrity,…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 51
- Next Page »